PRC2 is a histone methyltransferase complex composed of EZH2, SUZ12 and EED.8,9 Moreover, 3-deazaneplanocin A (DZNep), an inhibitor targeting PRC2, could inhibit the activity of S-adenosyl-L-homocysteine hydrolase.10 DZNep inhibits tumour characteristics,11,12 and its synergistic interaction with gemcitabine enhances tumour regulatory effects.13 However, the specific mechanisms underlying the metastatic regulation of HOTAIR in PCa are largely unclear. This evidence concerns the gene SUZ12 and posterior cortical atrophy.